ReviewCurrent gene therapy2009
Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.
Review in Current gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- The NF-κB Signalling Pathway: Mechanisms, Consequences and Therapeutic Targets.Journal of cellular and molecular medicine · 2026Review
- A thioridazine-derived molecule exhibits potential anti-inflammatory activity through IKK inhibition.Inflammopharmacology · 2025Article
- Neuro-inflammatory response dynamics following intestinal surgery: a mini-review.Frontiers in medicine · 2025Review
- Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease.European cardiology · 2023Review
- The Aging Heart: A Molecular and Clinical Challenge.International journal of molecular sciences · 2022Review
- The targets of aspirin in bladder cancer: bioinformatics analysis.BMC urology · 2022Article
- Gene therapy approaches for equine osteoarthritis.Frontiers in veterinary science · 2022Review
- The Expression of SOCS and NF-ϰB p65 in Hypopharyngeal Carcinoma.Iranian journal of public health · 2018Article
- Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.Antioxidants & redox signaling · 2018Review
- CRISPR/Cas9-mediated gene knockout reveals a guardian role of NF-κB/RelA in maintaining the homeostasis of human vascular cells.Protein & cell · 2018Article
- Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer.Oncology letters · 2018Article
- Repurposing Thioridazine (TDZ) as an anti-inflammatory agent.Scientific reports · 2018Article
- Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides.Drug delivery · 2017Review
- CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases.Biomedicines · 2017Review
- Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- Ageing, metabolism and cardiovascular disease.The Journal of physiology · 2016Review
- Cell-type specific penetrating peptides: therapeutic promises and challenges.Molecules (Basel, Switzerland) · 2015Review
- NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis.The Journal of pathology · 2014Article
- Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.International journal of oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear factor (NF)-kappaB is regarded as one of the most important transcription factors and plays an essential role in the transcriptional activation of pro-inflammatory cytokines, cell proliferation and survival. NF-kappaB can be activated via two distinct NF-kappaB signal transduction pathways, the so-called canonical and non-canonical pathways, and has been demonstrated to play a key role in a wide range of inflammatory diseases and various types of cancer. Much effort has been put in strategies to inhibit NF-kappaB activation, for example by the development of pharmacological compounds that selectively inhibit NF-kappaB activity and therefore would be beneficial for immunotherapy of transplantation, autoimmune and allergic diseases, as well as an adjuvant approach in patients treated with chemotherapy for cancer. Gene therapy targeting NF-kappaB is a promising new strategy with the potential of long-term effects and has been explored in a wide variety of diseases, ranging from cancer to transplantation medicine and autoimmune diseases. In this review we discuss recent progress made in the development of NF-kappaB targeted gene therapy and the evolution towards clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.